The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 31693879.
- Also identified by DOI 10.1016/j.cmet.2019.10.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher in a new paradigm in the treatment of heart failure.
Medical subject headings
- Benzhydryl Compounds
- Diabetes Mellitus, Type 2
- Glucosides
- Heart Failure
- Sodium-Glucose Transporter 2 Inhibitors